Genenta Science S.p.A. (NASDAQ:GNTA) on Tuesday said it is transitioning to a next-generation strategic industrial consolidator, focusing on acquiring privately held businesses in national-security regulated sectors.
• Genenta Science stock is gaining positive traction. What’s driving GNTA shares up?
Genenta’s Strategic Shift to the Defense Sector
The company plans to adopt the new name Saentra Forge S.p.A. and aims for majority ownership in companies generating up to approximately 5 million euros ($5.98 million) in EBITDA, starting with ATC, a defense-sector company.
In this context, Genenta has entered a binding agreement to fund ATC, a manufacturer of tactical rifles and special-forces weapon systems, with a total funding of 5.1 million euros planned. ATC is projected to achieve revenues of approximately 4 million euros in 2026, with expectations to double EBITDA in 2027, highlighting the strategic growth potential of this new direction.
The company’s governance structure centers on the Praexidia Foundation, a private-law entity, which is now a shareholder.
The company, the foundation, and founder and CEO Pierluigi Paracchi have signed a shareholders’ agreement that includes consultation rights on major corporate transactions and a renewable five-year lock-up.
The company said it has hit key clinical milestones that position its cell therapy platform for partnerships with major pharmaceutical and biotech players, which could speed development, improve market access, and enhance strategic value.
It has hired DC Advisory as the exclusive financial advisor to lead these partnership discussions.
The company plans to prioritize partnerships that expand the platform into broader applications and indications, particularly hard-to-treat solid tumors, including combination therapy strategies. It is also evaluating the continued development of Temferon as a monotherapy for glioblastoma multiforme (GBM).
Meanwhile, the company will continue advancing its GBM trial but intends to pursue a capital-efficient strategy by relying on partnerships for additional opportunities. It does not plan to internally advance the GU study or other clinical trials at this time.
Genenta’s Financial Outlook Amid Transformation
The stock is currently trading 87.5% above its 20-day simple moving average (SMA) of $1.39, and 10.6% above its 50-day SMA of $1.61, indicating short-term strength.
However, it is trading 10.6% below its 100-day SMA of $2.36 and 16.1% below its 200-day SMA of $3.10, suggesting longer-term challenges, as shares have decreased 68.29% over the past 12 months and are currently positioned closer to its 52-week lows than highs.
The RSI is at 34.40, which is considered neutral territory, while the MACD is above its signal line, indicating bullish momentum. The combination of neutral RSI and bullish MACD suggests mixed momentum, reflecting the stock’s potential for further upward movement amid recent news.
- Key Resistance: $3
- Key Support: $2
The company expects its cash, cash equivalents, and marketable securities at Dec. 31, 2025, to be approximately $33 million.
GNTA Price Action: Genenta Science shares surged more than 90%, reaching $2.50 during premarket trading on Tuesday before dropping to $1.38 at publication, according to Benzinga Pro data.
Photo: Elle Aon on Shutterstock
Recent Comments